Bristol-Myers Squibb Receives CHMP Positive Opinion For YERVOY? (ipilimumab) For Previously-Treated Patients With Metastatic Melanoma

YERVOY (ipilimumab) received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for the treatment of patients with previously-treated unresectable or metastatic melanoma. The European Commission will consider the CHMP's positive opinion in its decision on whether to grant a Marketing Authorisation by August 2011. "Despite the rising incidence of melanoma across Europe, no new treatment options have been approved in more than a decade...

Source: http://feedproxy.google.com/~r/mnt/healthnews/~3/qLoQaPHw2l8/226047.php

medical rehab sport